Results for the third quarter 2022

Another strong quarter ending at MNOK 116.5 in sales (MNOK 102.1), up 14.0 %. YTD revenue ended at MNOK 350.1 (MNOK 314.5), up 11.3 %

In the third quarter, total revenue ended at MNOK 116.5 (MNOK 102.1), a 14.0% increase. Sales growth is driven by the USA with a currency-neutral sales increase of 18.7 % for the quarter and 24.1 % YT. The Vascular business segment grows at 26.7 % for the quarter and 36.0 % YTD. The imaging products grows at 44.1 % for the quarter and 47.9 % YTD. Currency neutral sales of own products increase 14.7 % for the quarter and 11.8 % YTD. Operating profit (EBIT) for the quarter ended at MNOK 34.0 (MNOK 25.1), an EBIT margin of 29.2 % (24.6 %). Operating profit YTD ended at MNOK 104.8 (MNOK 96.8), an EBIT margin of 29.9 % (30.8 %).

See the full presentation and report below, as well as the video recording from the webinar.

Q3 2022 Presentation
Q3 2022 Financial Report